An appraisal of current systemic chemotherapy for psoriasis.
D000477:Alkylating Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000145:classification / Q000627:therapeutic use*; D001380:Azauridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002455:Cell Division; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007700:Kinetics; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008730:Methoxsalen / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D014467:Ultraviolet Therapy
D000477:Alkylating Agents; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001380:Azauridine; D009173:Mycophenolic Acid; D008730:Methoxsalen; D006918:Hydroxyurea; D008727:Methotrexate